FDA: Don't use medical food product Limbrel
The Food and Drug Administration is investigating serious adverse events involving Limbrel, a capsule being marketed as a medical food to manage the metabolic processes associated with osteoarthritis. Health care providers who know their patients are taking the product should advise them to stop taking it immediately, FDA said. While a range of adverse events have been reported, two serious and potentially life-threatening medical conditions are among them: drug-induced liver injury and hypersensitivity pneumonitis. For more information, see the FDA safety alert.
Related News Articles
Headline
The AHA’s Hospital Capacity Management Consortium will host a webinar Aug. 12 at 1 p.m. ET on how virtual nursing models can improve hospital throughput,…
Headline
The AHA’s American Organization for Nursing Leadership will host a webinar Aug. 5 at noon ET on how nurse leaders can guide ambient documentation from pilot…
Headline
The AHA July 27 expressed support for the National Nursing Workforce Center Act of 2025 (S. 1482), legislation that would establish state-based nursing…
Headline
The AHA’s American Organization for Nursing Leadership will host a biweekly virtual bootcamp from July 14-Aug. 25 for nurse executives and directors to provide…
Headline
The AHA will host a webinar April 16 at 1 p.m. ET featuring leaders from CHRISTUS Health and The Urology Group to share how nurse-first triage and smarter…
Headline
More than 100 members of Congress signed a letter submitted Dec. 12 to the Department of Education on concerns about the department’s proposal to omit post-…